Feeling Exhausted? Tuning Irf4 Energizes Dysfunctional T Cells. by Chennupati, V. & Held, W.
Immunity
Previewsinhibitors on immune cells can influence
anti-tumor immunity, a knowledge that is
needed to optimally combine these inhib-
itors with cancer immunotherapy.
In summary, the work by Coelho et al.
(2017) unveiled a novel molecular mecha-
nism of PD-L1 regulation that is controlled
by oncogenic RAS signaling. It highlights
the importance of non-cancer cell-auton-
omous mechanisms for tumor develop-
ment driven by major oncogenes like
RAS. The study also opens up new ave-
nues for the improvement of current can-
cer immunotherapies by targeting PD-L1
mRNA stability with small molecule inhib-
itors in tumors lacking genomic rear-
rangements of the PD-L1 30 UTR region.
As RASmutations and PD-L1 overexpres-
sion are common in human cancer, the
findings by Coelho et al. (2017) delineate
therapeutic strategies with broad clinical
applicability.
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The regulatory mechanisms governing T cell exhaustion remain incompletely understood. Man et al. (2017)
andWu et al. (2017) report that the T cell receptor responsive transcription factor Irf4 promotes T cell exhaus-
tion in chronic viral infection but dampens exhaustion in response to tissue allografts.T cell exhaustion refers to an alternative
differentiation program associated with
persistent antigen exposure, which is
characterized by reduced effector func-
tions, altered metabolic status, and
the transcriptional induction of negative
regulators of T cell function (Wherry
and Kurachi, 2015). While T cell exhaus-
tion reduces immune attack of healthy
tissues, it severely limits effector re-
sponses against chronic viral infec-tions and tumors. Accordingly, relieving
exhaustion has become a prime thera-
peutic focus to improve immune re-
sponses to chronic infection and cancer.
Conversely, promoting T cell exhaustion
may be a valuable approach to prevent
allograft rejection or control autoimmune
diseases.
Two papers in this issue of Immunity
address the role of interferon regulatory
factor 4 (Irf4) in the T cell response tochronic viral infection (Man et al., 2017)
and tissue allografts (Wu et al., 2017).
Despite substantial homology with other
members of the Irf family, Irf4 expression
is not induced by interferons but occurs
rapidly in response to T cell receptor
(TCR) stimulation. The level of Irf4 expres-
sion is proportional to the affinity of the
TCR for antigen and determines the
extent of clonal CD8+ T cell expansion
and effector differentiation in responsecember 19, 2017 ª 2017 Elsevier Inc. 1009
Figure 1. The Transcription Factor Irf4 Plays Opposing Roles in the Expression of
Exhaustion-Associated Genes in Response to Chronic Viral Infection and Tissue Allografts
Left: In CD8+ T cells responding to chronic viral infection, engagement of the T cell receptor (TCR) induces
the expression of Irf4, BATF, and NFATc1, whereby NFATc1 promotes Irf4 expression. Co-operation
between Irf4, BATF, and NFAT leads to the expression of exhaustion genes including Pdcd-1 (encoding
PD-1). The complete or partial absence of Irf4 reduces T cell exhaustion and PD-1 expression. Right: In
CD4+ T cells responding to allografts, TCR engagement induces Irf4 expression, which suppressesHelios.
The absence of Irf4 de-represses Helios, which then promotes PD-1 expression.
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Previewsto acute resolving infections (Man et al.,
2013; Yao et al., 2013).
In one of these new studies, Man et al.
(2017) show that Irf4 is overexpressed in
chronically activated as compared to
acutely stimulated CD8+ T cells. The
elevated levels of Irf4 drive CD8+ T cell
exhaustion, as complete or partial abla-
tion of Irf4 in T cells in mice by condi-
tional gene deletion reduces the surface
expression of multiple inhibitory recep-
tors, increases anabolic metabolism,
and improves the production of effector
cytokines such as IFN-g and TNF-a.
Lowered Irf4 expression does not
improve virus control, which may be ex-
plained by the reduced initial expansion
of virus-specific cells that also depends
on Irf4. However, lowered Irf4 expression
increases immune pathology, indicating
that residual CD8+ T cells exert height-
ened effector function (Man et al.,
2017). Thus, elevated Irf4 expression
promotes CD8+ T cell exhaustion in
chronic viral infection.1010 Immunity 47, December 19, 2017In the other study, Wu et al. (2017)
examine the role of Irf4 in heterotopic
heart allograft transplantation. In this
model, cessation of heartbeat serves as
a convenient and relevant readout for
graft rejection. It is important to note that
CD4+ rather than CD8+ T cells are neces-
sary and sufficient for allograft rejection in
this model. Like CD8+ T cells in chronic
infection, graft-infiltrating CD4+ T cells ex-
press high amounts of Irf4. Ablation of Irf4
in T cells completely prevents heart allo-
graft rejection. This observation is notable
as there are very few single gene knock-
outs in which the rejection of fully alloge-
neic transplants is completely prevented.
Regulatory T (Treg) cells do not explain
the absence of graft rejection, as Irf4-
deficient Treg cells are less suppressive
than wild-type and their depletion does
not result in rejection. Rather, the authors
demonstrate that alloantigen-specific
Irf4-deficient CD4+ T cells become
dysfunctional. Specifically, they overex-
press a subset of molecules associatedwith CD4+ T cell exhaustion, including
PD-1, CD160, and Helios (Ikzf2). Check-
point blockade using PD-L1- and CTLA-
4-specific antibodies improves the abun-
dance, proliferation, and effector cytokine
production by alloreactive CD4+ T cells
lacking Irf4. In addition, a significant frac-
tion of mice reject allografts when treated
with anti-PD-L1 alone or combined with
anti-CTLA-4, at least when treatment is
initiated during the first week following
transplantation (Wu et al., 2017). Thus,
reduced Irf4 expression promotes CD4+
T cell exhaustion and this results in stable
allograft acceptance.
Incidentally, checkpoint blockade at a
later stage does not lead to graft rejection,
indicating that Irf4-deficient CD4+ T cells
undergo progressive dysfunction that
becomes refractory to checkpoint inter-
vention (Wu et al., 2017). This type of
resistance is not apparent in chronic in-
fections as PD-1 blockade can still rein-
vigorate exhausted CD8+ T cells at even
later time points. Understanding this addi-
tional tolerance mechanism is of consid-
erable interest as it may provide further
targets to promote allograft tolerance.
Why does elevated Irf4 expression pro-
mote exhaustion in chronic infection and
prevent exhaustion in response to allo-
grafts? Irf4 binds the consensus ‘‘GAAA’’
DNA sequence but requires co-factors
for high-affinity binding. In T cells, Irf4 co-
operates with heterodimeric Jun-Basic
leucine zipper transcriptional factor ATF-
like (BATF) complexes, which bind AP-1-
Irf4 composite DNA elements (AICEs).
Irf4 can associate with additional tran-
scription factors, including NFAT and
others and, depending on the respective
interactions and the cellular context,
can mediate transcriptional activation or
repression (Huber and Lohoff, 2014).
Man et al. (2017) confirm that exhausted
CD8+ T cells overexpress several TCR-
responsive transcription factors including
Irf4, BATF, and NFATc1. Further, they
identify a feed forward loop in which
NFATc1 promotes Irf4 expression.
Finally, the analysis of publically available
genome-wide binding data shows that
Irf4, BATF, and NFATc2 are often re-
cruited to adjacent binding sites and pref-
erentially co-occupy genes that constitute
the exhaustion-specific gene signature,
which includes Pdcd-1 (encoding PD-1)
(Figure 1). Functionally, Irf4 and BATF
deficiencies lead to a corresponding
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et al., 2017), which is similar to earlier
NFAT loss-of-function experiments (Mar-
tinez et al., 2015), indicating that CD8+
T cell exhaustion is driven by the co-oper-
ation of a set of TCR-responsive tran-
scription factors.
In contrast, Wu et al. (2017) did not find
evidence for Irf4 association with the
Pdcd-1 locus in activated wild-type
CD4+ T cells. Rather, increased PD-1
expression correlates with the upregula-
tion and binding of Helios (Ikzf2) to the
Pdcd-1 locus. Indeed, enforced Helios
expression promotes PD-1 expression in
activated wild-type CD4+ T cells. As Irf4
represses Helios, PD-1 expression is not
induced in activated wild-type CD4+
T cells (Figure 1; Wu et al., 2017). The
notion that Irf4 plays distinct roles for
exhaustion of CD4+ versus CD8+ T cells
is supported by additional evidence. On
one hand, Wu et al. (2017) mention that
unlike the absence of Irf4, the absence
of BATF does not promote allograft toler-
ance, indicating that Irf4 acts indepen-
dently of BATF in CD4+ T cell exhaustion.
On the other hand, Helios expression is a
feature of exhausted CD4+ but not CD8+
T cells (Crawford et al., 2014). Collec-
tively, these data suggest that Irf4 plays
opposing roles in T cell exhaustion in
CD4+ versus CD8+ T cells. However, it re-
mains to be addressed whether differ-
ences in antigen distribution (systemic
versus non-hematopoietic tissue) and
the inflammatory milieu also influence
the role of Irf4.
Until recently, it was thought that
chronic viral infection precludes the for-
mation of CD8+ T cell memory. Contrary
to that assumption, it was recently shown
that a subset of antigen-specific CD8+
T cells, which express the transcription
factor Tcf1, sustain the response in
chronic infection by continuously produc-
ing exhausted cells lacking Tcf1 (Utzsch-
neider et al., 2016; Im et al., 2016). How
this memory-like compartment is gener-
ated and maintained is an obvious further
question. Man et al. (2017) find that ex-
hausted cells express significantly more
Irf4 than memory-like cells. Lowering Irf4
expression (using Irf4+/ T cells) pro-
foundly reduces the abundance of ex-
hausted cells but has a lesser impact onmemory-like cells (Man et al., 2017). Simi-
larly, reduced Irf4 expression had a more
substantial impact on the abundance of
terminal effector as compared to memory
precursor CD8+ T cells in acute resolving
infection (Nayar et al., 2014). Thus TCR-
responsive Irf4 appears to be particularly
important to drive conventional and
exhaustive CD8+ effector T cell differ-
entiation. In addition, memory-like CD8+
T cells mediate the proliferative burst in
response to PD-1 blockade (Utzschneider
et al., 2016; Im et al., 2016). Wu et al.
(2017) show that checkpoint blockade in-
creases the proliferation of alloreactive
CD4+ T cells lacking Irf4. This raises
the question of whether this proliferative
burst is also dependent on a subpopu-
lation of CD4+ T cells with memory-like
properties.
The fact that Irf4 is now shown to pro-
mote or repress dysfunctional T cell differ-
entiation may open opportunities to pre-
vent, reverse, and/or induce exhaustion
more specifically in T cells responding to
antigen. Along this line, Man et al. (2017)
show that the NFAT inhibitor Cyclosporin
A reduces Irf4 expression in activated
CD8+ T cells, and there is evidence that
this immunosuppressive drug reduces
the induction of PD-1 in CD8+ T cells.
Wu et al. (2017) screened cytokines and
small molecule inhibitors for their capacity
to tune Irf4 expression. They find that
the MEK1/2 inhibitor Trametinib reduces
Irf4 and upregulates Helios and PD-1
expression in activated CD4+ T cells.
Moreover, Trametinib significantly ex-
tends allograft survival in wild-type mice
(Wu et al., 2017). Further investigation
will be needed to address to what extent
the reduced rejection is due to the induc-
tion of T cell exhaustion. Irrespectively,
these data provide a proof of concept
that pharmacological inhibition of Irf4 is
feasible.
Taken together, the new results reveal
unexpected insights into the regulation
of T cell exhaustion. While de-repressing
exhausted T cells to enhance tumor im-
mune responses is a medical success
story, these new studies raise the pros-
pect of inducing T cell exhaustion to
obstruct unwanted immune responses in
order to reduce transplant rejection or
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